I don't have much to add to the discussion here, but I would like people to know that OCF is a funder of RTOG1016 (part of your donations at work), and purchased and disseminated 100 iPads preprogrammed with a questionnaire that all patients enrolled in the clinical trial will be filling out regularly during their treatment visits. OCF is trying to access the quality of life of patients during and after treatments regardless of which arm of the trial they are in. Most of us know here that QOL in patients is a grossly over looked piece of the puzzle. Improving that starts with gathering data on what the experience is really like in an objective manner, not heard second had from treatment facilities, but as expressed by the patients themselves.

As others have said, working on a trial that has Dr. Gillison's participation is very taxing but fulfilling. She is driven to find the answers, and OCF and I a proud to be working on our 9th investigation with her as participants, recruiters, funders, and data compilers. I am particularly eager for this trial to be filled completely so the data faucet will begin to flow.

For those that have been through it Cisplatin treatment is not walk in the park, and this is a first look if a less toxic monoclonal antibody will have the same clinical end results when replacing it.